Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

McMaster University

$100,000.00

Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial

FY 2015-16

Summary
Forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. Spironlactone is a drug that is very effective at reducing heart related deaths and hospitalizations in patients with heart failure that do not also have kidney failure. It does this by reducing scarring of the heart. Kidney failure appears to trigger progressive changes in the heart that also lead to heart scarring and heart failure which, in turn, is a major cause of heart related deaths. It therefore makes sense that spironolactone would work in patients with kidney failure. However, there are no studies to tell us if spironolactone will benefit patients with kidney failure and as a result, only 1% of kidney failure patients receive spironolactone or spironolactone-like drugs. It is important to determine if spironolactone has benefits for patients with kidney failure because, if it does, there is an opportunity to reduce heart related deaths and hospitalizations. We will perform a large study in several countries that will give physicians and patients the information they need to determine if spironolactone reduces heart related deaths and hospitalizations. We call this study the Protection of the Heart with Aldosterone antagoniSm in End stage renal disease (PHASE 2) trial.
Program
Operating Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
333015
Name
Walsh Michael W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Aldosterone; End-Stage Renal Disease; Hemodialysis; Randomized Controlled Trial; Spironolactone
Abstract
Forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. Spironlactone is a drug that is very effective at reducing heart related deaths and hospitalizations in patients with heart failure that do not also have kidney failure. It does this by reducing scarring of the heart. Kidney failure appears to trigger progressive changes in the heart that also lead to heart scarring and heart failure which, in turn, is a major cause of heart related deaths. It therefore makes sense that spironolactone would work in patients with kidney failure. However, there are no studies to tell us if spironolactone will benefit patients with kidney failure and as a result, only 1% of kidney failure patients receive spironolactone or spironolactone-like drugs. It is important to determine if spironolactone has benefits for patients with kidney failure because, if it does, there is an opportunity to reduce heart related deaths and hospitalizations. We will perform a large study in several countries that will give physicians and patients the information they need to determine if spironolactone reduces heart related deaths and hospitalizations. We call this study the Protection of the Heart with Aldosterone antagoniSm in End stage renal disease (PHASE 2) trial.
Competitiondate
201504
Approvedterm2
1 yr 0 mth
Pinamesdelim
Walsh, Michael W; Wald, Ron
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~